TY - JOUR
T1 - Freestyle aortic root bioprosthesis is a suitable alternative for aortic root replacement in elderly patients
T2 - A propensity score study
AU - Mazzola, Alessandro
AU - Di Mauro, Michele
AU - Pellone, Francesco
AU - Faragalli, Francesca
AU - Villani, Carmine
AU - Di Eusanio, Mauro
AU - Gizzi, Germana
AU - Lemme, Erika
AU - Gregorini, Renato
AU - Romano, Silvio
AU - Penco, Maria
PY - 2012/10
Y1 - 2012/10
N2 - Background: The aim of this retrospective study was to compare the early and midterm clinical outcomes of aortic root replacement in elderly patients receiving the Freestyle stentless bioprosthesis (FSB) (Medtronic Inc, Minneapolis, MN) with younger patients receiving a mechanical valve conduit. Methods: From January 2001 to December 2010, 185 consecutive patients underwent aortic root replacement. Of these, 79 (43%) patients received the Freestyle bioroot (Medtronic Inc, Minneapolis, MN) (group F) and 106 (57%) patients received a mechanical valve conduit (group M). Target endpoints were 30-day mortality, 5-year survival, 5-year freedom from cardiac death, and 5-year freedom from major adverse valve-related and cardiovascular events (MAVCE) (cardiac death, cerebrovascular accident, myocardial infarction, heart failure, valve prosthesis dysfunction requiring reoperation, and thromboembolic and hemorrhagic events). A propensity score model was built to adjust the results according to preoperative and operative characteristics of both groups. Results: Thirty-day mortality was similar in both groups (F group, 2.5% versus M group, 5.7%; p = 0.407). Unadjusted analysis showed no differences between groups, whereas adjusted analysis showed a significantly higher 5-year freedom from cardiac death and MAVCE in group F (group F, 98.6 ± 1.9 versus group M, 88.0% ± 3.0%; p = 0.038; group F, 97.4% ± 2.6% versus group M, 81.2% ± 3.6%; p = 0.010). Multivariate analysis confirmed a significantly higher risk for 5-year MAVCE in patients who did not undergo implantation with the Freestyle bioprosthesis (hazard ratio [HR], 6.87; 95% confidence limit [CL], 1.43-15.09; p = 0.016). Conclusions: In elderly patients, the FSB seems to be as safe as mechanical composite grafts in the perioperative period but results in superior freedom from MAVCE at 5 years postoperatively.
AB - Background: The aim of this retrospective study was to compare the early and midterm clinical outcomes of aortic root replacement in elderly patients receiving the Freestyle stentless bioprosthesis (FSB) (Medtronic Inc, Minneapolis, MN) with younger patients receiving a mechanical valve conduit. Methods: From January 2001 to December 2010, 185 consecutive patients underwent aortic root replacement. Of these, 79 (43%) patients received the Freestyle bioroot (Medtronic Inc, Minneapolis, MN) (group F) and 106 (57%) patients received a mechanical valve conduit (group M). Target endpoints were 30-day mortality, 5-year survival, 5-year freedom from cardiac death, and 5-year freedom from major adverse valve-related and cardiovascular events (MAVCE) (cardiac death, cerebrovascular accident, myocardial infarction, heart failure, valve prosthesis dysfunction requiring reoperation, and thromboembolic and hemorrhagic events). A propensity score model was built to adjust the results according to preoperative and operative characteristics of both groups. Results: Thirty-day mortality was similar in both groups (F group, 2.5% versus M group, 5.7%; p = 0.407). Unadjusted analysis showed no differences between groups, whereas adjusted analysis showed a significantly higher 5-year freedom from cardiac death and MAVCE in group F (group F, 98.6 ± 1.9 versus group M, 88.0% ± 3.0%; p = 0.038; group F, 97.4% ± 2.6% versus group M, 81.2% ± 3.6%; p = 0.010). Multivariate analysis confirmed a significantly higher risk for 5-year MAVCE in patients who did not undergo implantation with the Freestyle bioprosthesis (hazard ratio [HR], 6.87; 95% confidence limit [CL], 1.43-15.09; p = 0.016). Conclusions: In elderly patients, the FSB seems to be as safe as mechanical composite grafts in the perioperative period but results in superior freedom from MAVCE at 5 years postoperatively.
UR - http://www.scopus.com/inward/record.url?scp=84866654622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866654622&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2012.05.015
DO - 10.1016/j.athoracsur.2012.05.015
M3 - Article
C2 - 22748645
AN - SCOPUS:84866654622
SN - 0003-4975
VL - 94
SP - 1185
EP - 1190
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 4
ER -